1.Wogonin Attenuates Hippocampal Neuronal Loss and Cognitive Dysfunction in Trimethyltin-Intoxicated Rats.
Bombi LEE ; Bongjun SUR ; Seong Guk CHO ; Mijung YEOM ; Insop SHIM ; Hyejung LEE ; Dae Hyun HAHM
Biomolecules & Therapeutics 2016;24(3):328-337
We examined whether wogonin (WO) improved hippocampal neuronal activity, behavioral alterations and cognitive impairment, in rats induced by administration of trimethyltin (TMT), an organotin compound that is neurotoxic to these animals. The ability of WO to improve cognitive efficacy in the TMT-induced neurodegenerative rats was investigated using a passive avoidance test, and the Morris water maze test, and using immunohistochemistry to detect components of the acetylcholinergic system, brain-derived neurotrophic factor (BDNF), and cAMP-response element-binding protein (CREB) expression. Rats injected with TMT showed impairments in learning and memory and daily administration of WO improved memory function, and reduced aggressive behavior. Administration of WO significantly alleviated the TMT-induced loss of cholinergic immunoreactivity and restored the hippocampal expression levels of BDNF and CREB proteins and their encoding mRNAs to normal levels. These findings suggest that WO might be useful as a new therapy for treatment of various neurodegenerative diseases.
Animals
;
Brain-Derived Neurotrophic Factor
;
Cholinergic Neurons
;
Cognition Disorders
;
Cyclic AMP Response Element-Binding Protein
;
Immunohistochemistry
;
Learning
;
Memory
;
Neurodegenerative Diseases
;
Neurons*
;
Rats*
;
RNA, Messenger
;
Water
2.Effect of Beta-Asarone on Impairment of Spatial Working Memory and Apoptosis in the Hippocampus of Rats Exposed to Chronic Corticosterone Administration.
Bombi LEE ; Bongjun SUR ; Seong Guk CHO ; Mijung YEOM ; Insop SHIM ; Hyejung LEE ; Dae Hyun HAHM
Biomolecules & Therapeutics 2015;23(6):571-581
beta-asarone (BAS) is an active component of Acori graminei rhizoma, a traditional medicine used clinically in treating dementia and chronic stress in Korea. However, the cognitive effects of BAS and its mechanism of action have remained elusive. The purpose of this study was to examine whether BAS improved spatial cognitive impairment induced in rats following chronic corticosterone (CORT) administration. CORT administration (40 mg/kg, i.p., 21 days) resulted in cognitive impairment in the avoidance conditioning test (AAT) and the Morris water maze (MWM) test that was reversed by BAS (200 mg/kg, i.p). Additionally, as assessed by immunohistochemistry and RT-PCR analysis, the administration of BAS significantly alleviated memory-associated decreases in the expression levels of brain-derived neurotrophic factor (BDNF) and cAMP-response element-binding protein (CREB) proteins and mRNAs in the hippocampus. Also, BAS administration significantly restored the expression of Bax and Bcl-2 mRNAs in the hippocampus. Thus, BAS may be an effective therapeutic for learning and memory disturbances, and its neuroprotective effect was mediated, in part, by normalizing the CORT response, resulting in regulation of BDNF and CREB functions and anti-apoptosis in rats.
Animals
;
Apoptosis*
;
Brain-Derived Neurotrophic Factor
;
Corticosterone*
;
Dementia
;
Hippocampus*
;
Immunohistochemistry
;
Korea
;
Learning
;
Medicine, Traditional
;
Memory
;
Memory, Short-Term*
;
Neuroprotective Agents
;
Rats*
;
RNA, Messenger
;
Water
3.Insulin Secretion and Incretin Hormone Concentration in Women with Previous Gestational Diabetes Mellitus.
Sung Hoon YU ; Bongjun CHO ; Yejin LEE ; Eunhye KIM ; Sung Hee CHOI ; Soo LIM ; Ka Hee YI ; Young Joo PARK ; Kyong Soo PARK ; Hak Chul JANG
Diabetes & Metabolism Journal 2011;35(1):58-64
BACKGROUND: We examined the change in the levels of incretin hormone and effects of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) on insulin secretion in women with previous gestational diabetes (pGDM). METHODS: A 75-g oral glucose tolerance test (OGTT) was conducted on 34 women with pGDM. In addition, 11 women with normal glucose tolerance, matched for age, height and weight, were also tested. The insulin, GIP, GLP-1, and glucagon concentrations were measured, and their anthropometric and biochemical markers were also measured. RESULTS: Among 34 women with pGDM, 18 had normal glucose tolerance, 13 had impaired glucose tolerance (IGT) and 1 had diabetes. No significant differences were found in GLP-1 concentration between the pGDM and control group. However, a significantly high level of glucagon was present in the pGDM group at 30 minutes into the OGTT. The GIP concentration was elevated at 30 minutes and 60 minutes in the pGDM group. With the exception of the 30-minute timepoint, women with IGT had significantly high blood glucose from 0 to 120 minutes. However, there was no significant difference in insulin or GLP-1 concentration. The GIP level was significantly high from 0 to 90 minutes in patients diagnosed with IGT. CONCLUSION: GLP-1 secretion does not differ between pGDM patients and normal women. GIP was elevated, but that does not seem to induce in increase in insulin secretion. Therefore, we conclude that other factors such as heredity and environment play important roles in the development of type 2 diabetes.
Biomarkers
;
Blood Glucose
;
Diabetes, Gestational
;
Female
;
Glucagon
;
Glucagon-Like Peptide 1
;
Glucose
;
Glucose Tolerance Test
;
Heredity
;
Humans
;
Incretins
;
Insulin
;
Pregnancy